Incyte’s Minjuvi gains Australian reimbursement after TGA follicular lymphoma registration
Australia has listed Minjuvi on the PBS for relapsed follicular lymphoma. See what the inMIND data and access terms mean.
Pharma & Biotech
Pharma & Biotech
Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?
Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.
Pharma & Biotech
Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL
Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.
Pharma & Biotech
Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?
Incyte’s Phase 3 tafasitamab data are headed to ASCO 2026. Read what frontMIND could change for first-line DLBCL and what risks still remain.
Pharma & Biotech
Incyte’s tafasitamab clears pivotal trial in high-risk DLBCL—will it shift front-line treatment?
Incyte Corporation has announced positive topline results from its Phase 3 frontMIND trial evaluating tafasitamab (marketed as Monjuvi/Minjuvi) and lenalidomide in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of progression-free survival (PFS) and a key secondary endpoint of event-free survival (EFS), setting the stage for
Pharma & Biotech
Incyte’s Minjuvi combo gets Japan approval for relapsed follicular lymphoma
Incyte Biosciences Japan has secured approval from the Ministry of Health, Labour and Welfare for the use of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma. This marks the first regulatory authorization in Japan for a CD19-directed therapy in this indication and introduces a novel CD19–CD20